Glanzmann's thrombasthenia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:


Patients suffering from Glanzmann's thrombasthenia thus have platelets less able to adhere to each other and to the underlying tissue of damaged blood vessels.
Patients suffering from Glanzmann's thrombasthenia thus have platelets less able to adhere to each other and to the underlying tissue of damaged blood vessels.
Integrin (ITG) αIIbβ3 has roll in platelet aggregation and adhesion, connection between cells, cell migration and thrombus formation. 


The understanding of its pathophysiology led to the development of [[GpIIb/IIIa inhibitors]], a class of powerful [[antiplatelet agent]]s.<ref name="seligsohn">Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. [http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=73569&ProduktNr=224034&Ausgabe=229381&filename=73569.pdf Free Full Text].</ref>
The understanding of its pathophysiology led to the development of [[GpIIb/IIIa inhibitors]], a class of powerful [[antiplatelet agent]]s.<ref name="seligsohn">Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. [http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=73569&ProduktNr=224034&Ausgabe=229381&filename=73569.pdf Free Full Text].</ref>


==Pathophysiology ==
==Pathophysiology ==
Integrin (ITG) αIIbβ3, formerly known as GPIIb/IIIa<ref name="pmid21917754">{{cite journal| author=Nurden AT, Fiore M, Nurden P, Pillois X| title=Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. | journal=Blood | year= 2011 | volume= 118 | issue= 23 | pages= 5996-6005 | pmid=21917754 | doi=10.1182/blood-2011-07-365635 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917754  }}</ref> is a large heterodimeric cell transmembrane receptor consists of a larger αIIb and a smaller β3 subunit. These subunits are non-covalently linked, allowing for duplex signaling between the cell membrane and extracellular matrix, while instituting intracellular signaling pathways.This heterodimer a 8×12 nm nodular head and two 18 nm stalks in electron microscope. <ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue=  | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478  }}</ref>
Integrin (ITG) αIIbβ3, formerly known as GPIIb/IIIa<ref name="pmid21917754">{{cite journal| author=Nurden AT, Fiore M, Nurden P, Pillois X| title=Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. | journal=Blood | year= 2011 | volume= 118 | issue= 23 | pages= 5996-6005 | pmid=21917754 | doi=10.1182/blood-2011-07-365635 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917754  }}</ref> is a large heterodimeric cell transmembrane receptor consists of a larger αIIb and a smaller β3 subunit. These subunits are non-covalently linked, allowing for duplex signaling between the cell membrane and extracellular matrix, while instituting intracellular signaling pathways.
 
ITG αIIbβ3 has a 8×12 nm nodular head and two 18 nm stalks in electron microscope. These stalks have both transmembrane and cytoplasmic sides,which intracellular signaling proteins and molecules can attach to them, on the other hand the domain that binds to ligand is located in the head
 
Hematopoietic stem cell generates ITG αIIbβ3. Integrin αIIbβ3 needs calcium for it’s function, the αIIb subunit is made of a single peptide, is cinnected to the megakaryocyte lineage includes β-propeller area, which takes part in making a compound binding to calcium and platelet to platelet adhesion. ITG αIIbβ3 is activated through the attachment with epidermal growth factor (EGF) site of the β3 subunit. The platelet aggregation is through binding the receptor in head with vitronectin, VWF, fibronectin and fibrinogen.
 
GPIIIa  on platelet is coded by ITGB3, a gene on chromosome 17q21. Whereas GPαIIb is coded by the gene ITGA2B, again on chromosome 17q21.
 
The amount of GPIIb/IIIa receptor on platelet’s surface varies by two-fold between patients, therefore platelet consists of about 100,000 GPIIb/IIIa receptor copies. Platelet aggregates normally with only 50% gene-producing protein, hence mutation in these genes consequently defects  fibrinogen receptor αIIbβ3 and platelet’s function. Mutations can be, insertions, deletions,nonsense, missense or frameshifts and in ITGA2B gene occur these mutations more, because ITGA2B has more exon (30 exon ) than ITGB3 gene (15 exon ).  <ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue=  | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478  }}</ref>


==References==
==References==

Revision as of 06:43, 8 July 2018

Glanzmann's thrombasthenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glanzmann's thrombasthenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glanzmann's thrombasthenia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glanzmann's thrombasthenia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glanzmann's thrombasthenia pathophysiology

CDC on Glanzmann's thrombasthenia pathophysiology

Glanzmann's thrombasthenia pathophysiology in the news

Blogs on Glanzmann's thrombasthenia pathophysiology

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Glanzmann's thrombasthenia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The GpIIb/IIIa is an adhesion receptor and is expressed in thrombocytes. This receptor is activated when the thrombocyte is stimulated by ADP, epinephrine, collagen and thrombin. The GpIIb/IIIa integrin is essential to the blood coagulation since it has the ability to bind fibrinogen, the von Willebrand factor, fibronectin and vitronectin. This enables the platelet to be activated by contact with the collagen-von Willebrand-complex that is exposed when the endothelial blood vessel lining is damaged and then aggregate with other thrombocytes via fibrinogen.

Patients suffering from Glanzmann's thrombasthenia thus have platelets less able to adhere to each other and to the underlying tissue of damaged blood vessels.

Integrin (ITG) αIIbβ3 has roll in platelet aggregation and adhesion, connection between cells, cell migration and thrombus formation. 

The understanding of its pathophysiology led to the development of GpIIb/IIIa inhibitors, a class of powerful antiplatelet agents.[1]

Pathophysiology

Integrin (ITG) αIIbβ3, formerly known as GPIIb/IIIa[2] is a large heterodimeric cell transmembrane receptor consists of a larger αIIb and a smaller β3 subunit. These subunits are non-covalently linked, allowing for duplex signaling between the cell membrane and extracellular matrix, while instituting intracellular signaling pathways.

ITG αIIbβ3 has a 8×12 nm nodular head and two 18 nm stalks in electron microscope. These stalks have both transmembrane and cytoplasmic sides,which intracellular signaling proteins and molecules can attach to them, on the other hand the domain that binds to ligand is located in the head. 

Hematopoietic stem cell generates ITG αIIbβ3. Integrin αIIbβ3 needs calcium for it’s function, the αIIb subunit is made of a single peptide, is cinnected to the megakaryocyte lineage includes β-propeller area, which takes part in making a compound binding to calcium and platelet to platelet adhesion. ITG αIIbβ3 is activated through the attachment with epidermal growth factor (EGF) site of the β3 subunit. The platelet aggregation is through binding the receptor in head with vitronectin, VWF, fibronectin and fibrinogen.

GPIIIa  on platelet is coded by ITGB3, a gene on chromosome 17q21. Whereas GPαIIb is coded by the gene ITGA2B, again on chromosome 17q21.

The amount of GPIIb/IIIa receptor on platelet’s surface varies by two-fold between patients, therefore platelet consists of about 100,000 GPIIb/IIIa receptor copies. Platelet aggregates normally with only 50% gene-producing protein, hence mutation in these genes consequently defects  fibrinogen receptor αIIbβ3 and platelet’s function. Mutations can be, insertions, deletions,nonsense, missense or frameshifts and in ITGA2B gene occur these mutations more, because ITGA2B has more exon (30 exon ) than ITGB3 gene (15 exon ).  [3]

References

  1. Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.
  2. Nurden AT, Fiore M, Nurden P, Pillois X (2011). "Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models". Blood. 118 (23): 5996–6005. doi:10.1182/blood-2011-07-365635. PMID 21917754.
  3. Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.